16th International AIDS Conference


Toronto, Canada - August 13 - 18, 2006

HUMAN IMMUNODEFICIENCY VIRUS TYPES 1 AND 2 HAVE DIFFERENT REPLICATION KINETICS IN HUMAN PRIMARY MACROPHAGE CULTURE

Int Conf AIDS. 2006 Aug 13-18;16 Abstract No. TuAa0105

D. Marchant1, S.J.D. Neil2, Á. McKnight2
1 University of British Columbia, The James Hogg iCAPTURE centre, Vancouver, United Kingdom, 2 Wohl Virion Centre, Windeyer Institute of Medical Sciences, UCL, London, United Kingdom

Human immunodeficiency viruses type 2 (HIV-2) and type 1 (HIV-1) both infect CD4+ myeloid and lymphoid cells in the human host. HIV-1, however, is more virulent than HIV-2 and is the cause of the current pandemic. The HIV-2 epidemic is restricted primarily to West Africa and is currently declining. This study compares the replication of primary isolates of HIV-2 and HIV-1 in monocyte-derived macrophages (MDMs). Eleven HIV-2 and five HIV-1 primary isolates that use CCR5, CXCR4 or both coreceptors to enter cells were included. Regardless of coreceptor preference, 10 of 11 HIV-2 viruses could enter, reverse transcribe and produce fully infectious virus in MDMs with efficiency equal to that in peripheral blood mononuclear cells. However, the kinetics of replication of HIV-2 compared with HIV-1 over time were distinct. HIV-2 had a burst of virus replication 2 days after infection that resolved into an apparent "latent state" at day 3. HIV-1, however, continued to produce infectious virions at a lower, but steady, rate throughout the course of infection. These results may have implications for the lower pathogenesis and viral-load characteristics of HIV-2 infection.

Acrobat ReaderDownload PDF of this abstract.

Power Point PresentationDownload Power Point Presentation.

2006-08-13
TuAa0105

Copyright © 2006 - International AIDS Society (IAS). All information and content relating to the abstracts from the 16th International AIDS Conference, such as text, graphics, logos, button icons, images, audio clips, and software is protected by copyright. Permission is hereby granted for the non-commercial use or reproduction of the information on this web site, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.

AEGiS is a 501c(3) not-for-profit organization made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, GlaxoSmithKline, the National Library of Medicine, Roche / Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 2006. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2006. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. Permission is hereby granted for the non-commercial use or reproduction of the information herein, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.